ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.647,34
0,25%
Brent Oil
81,295
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. aTyr Pharma Inc (LIFE)

  7. aTyr Pharma Inc (LIFE) Notícias

LIFE

aTyr Pharma (LIFE)

aTyr Pharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LIFE
DataHoraFonteTítuloCódigoCompanhia
29/05/202417:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
24/05/202417:00GlobeNewswire Inc.aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LIFEaTyr Pharma Inc
23/05/202420:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
15/05/202408:00GlobeNewswire Inc.aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceNASDAQ:LIFEaTyr Pharma Inc
14/05/202409:00GlobeNewswire Inc.aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:LIFEaTyr Pharma Inc
06/05/202409:00GlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
02/05/202417:00GlobeNewswire Inc.aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
01/04/202409:00GlobeNewswire Inc.aTyr Pharma to Participate in April Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
14/03/202417:00GlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
28/02/202410:00GlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsNASDAQ:LIFEaTyr Pharma Inc
21/02/202410:00GlobeNewswire Inc.aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsNASDAQ:LIFEaTyr Pharma Inc
29/01/202410:00GlobeNewswire Inc.aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityNASDAQ:LIFEaTyr Pharma Inc
18/01/202410:00GlobeNewswire Inc.aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorNASDAQ:LIFEaTyr Pharma Inc
02/01/202414:21Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIFEaTyr Pharma Inc
21/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIFEaTyr Pharma Inc
13/11/202310:00GlobeNewswire Inc.aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023NASDAQ:LIFEaTyr Pharma Inc
09/11/202319:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIFEaTyr Pharma Inc
09/11/202318:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIFEaTyr Pharma Inc
09/11/202318:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIFEaTyr Pharma Inc
09/11/202318:00GlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
01/11/202309:00GlobeNewswire Inc.aTyr Pharma to Present at November Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
31/10/202309:00GlobeNewswire Inc.aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDNASDAQ:LIFEaTyr Pharma Inc
11/09/202309:00GlobeNewswire Inc.aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported OutcomesNASDAQ:LIFEaTyr Pharma Inc
24/08/202309:00GlobeNewswire Inc.aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LIFEaTyr Pharma Inc
10/08/202317:07Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LIFEaTyr Pharma Inc
09/08/202317:00GlobeNewswire Inc.aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
22/06/202309:00GlobeNewswire Inc.European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic SclerosisNASDAQ:LIFEaTyr Pharma Inc
20/06/202309:00GlobeNewswire Inc.aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) ConferenceNASDAQ:LIFEaTyr Pharma Inc
06/06/202309:00GlobeNewswire Inc.aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)NASDAQ:LIFEaTyr Pharma Inc
25/05/202309:00GlobeNewswire Inc.aTyr Pharma to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:LIFEaTyr Pharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:LIFE

Seu Histórico Recente

COIN
WORLDETH
World Token
BIT
UC611Z
Unicredit Bank
BIT
F38920
Vontobel Financial Produ...
BIT
UC72MQ
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados